NASDAQ:KMDA - Kamada Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$5.45 +0.05 (+0.93 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$5.40
Today's Range$5.35 - $5.50
52-Week Range$4.15 - $6.10
Volume5,400 shs
Average Volume20,883 shs
Market Capitalization$209.37 million
P/E Ratio30.28
Dividend YieldN/A
Beta1.22
Kamada logoKamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD). It also provides immunoglobulin products that comprise KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho(D)IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company offers other products, including Heparin Lock Flush to maintain patency of indwelling IV catheter; Kamacaine 0.5% used as anesthesia for surgery, diagnostic, therapeutic, and obstetrical procedures, as well as spinal anesthesia for surgery; and Human Transferrin, which is used as a cultural medium for diagnostic assays and cell cultures. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. Additionally, it provides Heparin sodium injection to treat thrombo-embolic disorders; and Albumin for maintenance of blood plasma. Kamada Ltd. also offers coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Baxter International Inc.; Chiesi Farmaceutici; PARI GmbH; and Kedrion S.p.A. The company was founded in 1990 and is headquartered in Rehovot, Israel.

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Debt-to-Equity Ratio0.01
Current Ratio3.95
Quick Ratio2.85

Price-To-Earnings

Trailing P/E Ratio30.28
Forward P/E Ratio24.77
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.82 million
Price / Sales2.13
Cash Flow$0.2709 per share
Price / Cash20.12
Book Value$2.22 per share
Price / Book2.45

Profitability

EPS (Most Recent Fiscal Year)$0.18
Net Income$6.90 million
Net Margins11.79%
Return on Equity14.43%
Return on Assets10.84%

Miscellaneous

Employees413
Outstanding Shares40,260,000
Market Cap$209.37 million

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Tuesday, August, 7th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The biotechnology company had revenue of $33.84 million for the quarter, compared to analysts' expectations of $29.64 million. Kamada had a net margin of 11.79% and a return on equity of 14.43%. View Kamada's Earnings History.

When is Kamada's next earnings date?

Kamada is scheduled to release their next quarterly earnings announcement on Monday, November, 12th 2018. View Earnings Estimates for Kamada.

What price target have analysts set for KMDA?

3 Wall Street analysts have issued 1 year target prices for Kamada's stock. Their predictions range from $7.00 to $11.00. On average, they anticipate Kamada's share price to reach $8.3333 in the next twelve months. This suggests a possible upside of 52.9% from the stock's current price. View Analyst Price Targets for Kamada.

What is the consensus analysts' recommendation for Kamada?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada.

Who are some of Kamada's key competitors?

Who are Kamada's key executives?

Kamada's management team includes the folowing people:
  • Mr. Amir London, Chief Exec. Officer (Age 49)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 67)
  • Dr. Liliana Bar, VP of R&D & IP (Age 63)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 48)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 45)

Has Kamada been receiving favorable news coverage?

Media headlines about KMDA stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Kamada earned a news impact score of 0.20 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Kamada.

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.15%), Acadian Asset Management LLC (0.73%), ARK Investment Management LLC (0.30%), Macquarie Group Ltd. (0.12%) and Jane Street Group LLC (0.07%).

Which major investors are buying Kamada stock?

KMDA stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Jane Street Group LLC, Macquarie Group Ltd. and ARK Investment Management LLC.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.45.

How big of a company is Kamada?

Kamada has a market capitalization of $209.37 million and generates $102.82 million in revenue each year. The biotechnology company earns $6.90 million in net income (profit) each year or $0.18 on an earnings per share basis. Kamada employs 413 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (NASDAQ KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  322
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2018 by MarketBeat.com Staff

Featured Article: Outstanding Shares

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.